|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/14/20 Cell MedX Corp. 10-Q 2/29/20 67:2.2M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 353K
6: EX-10.60 Loan Agreement and Note Payable Dated December 3, HTML 26K
2019, Among Cell Medx Corp. and Longview
Investment Limited
7: EX-10.61 Loan Agreement and Note Payable Dated January 6, HTML 26K
2020, Among Cell Medx Corp. and Longview
Investment Limited
8: EX-10.62 Loan Agreement and Note Payable Dated January 9, HTML 26K
2020, Among Cell Medx Corp. and Longview
Investment Limited
9: EX-10.63 Loan Agreement and Note Payable Dated January 31, HTML 26K
2020, Among Cell Medx Corp. and Longview
Investment Limited
10: EX-10.65 Loan Agreement and Note Payable Dated February 17, HTML 26K
2020, Among Cell Medx Corp. and Longview
Investment Limited
11: EX-10.66 Loan Agreement and Note Payable Dated March 4, HTML 26K
2020, Among Cell Medx Corp. and Longview
Investment Limited
12: EX-10.67 Loan Agreement and Note Payable Dated March 25, HTML 26K
2020, Among Cell Medx Corp. and Longview
Investment Limited
2: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
26: R1 Document and Entity Information HTML 69K
41: R2 Condensed Consolidated Balance Sheets HTML 99K
63: R3 Condensed Consolidated Balance Sheets - HTML 28K
Parenthetical
30: R4 Condensed Consolidated Statements of Operations HTML 92K
27: R5 Condensed Consolidated Statement of Stockholders' HTML 69K
Deficit
42: R6 Condensed Consolidated Statements of Cash Flows HTML 94K
64: R7 Organization and Nature of Operations HTML 29K
33: R8 Related Party Transactions Disclosure HTML 36K
25: R9 Inventory Disclosure HTML 25K
19: R10 Other Current Assets Disclosure HTML 23K
37: R11 Equipment Disclosure HTML 28K
58: R12 Unearned Revenue Disclosure HTML 37K
52: R13 Revenue Disclosure HTML 27K
20: R14 Notes and Advances Payable Disclosure HTML 43K
38: R15 Share Capital Disclosure HTML 49K
59: R16 Subsequent Event Disclosure HTML 26K
53: R17 Organization and Nature of Operations: Going HTML 25K
Concern (Policies)
21: R18 Related Party Transactions Disclosure: Schedule of HTML 28K
Amounts Due to Related Parties (Tables)
36: R19 Related Party Transactions Disclosure: Schedule of HTML 27K
Transactions with Related Parties (Tables)
66: R20 Equipment Disclosure: Amortization schedule for HTML 27K
the equipment (Tables)
45: R21 Unearned Revenue Disclosure: Changes to Unearned HTML 28K
Revenue (Tables)
28: R22 Unearned Revenue Disclosure: Schedule of Loss on HTML 25K
Reacquisition of Distribution Rights (Tables)
34: R23 Revenue Disclosure: Schedule of Revenue and HTML 27K
Associated Costs (Tables)
67: R24 Notes and Advances Payable Disclosure: Schedule of HTML 35K
Short-term Loans and Advances Outstanding (Tables)
46: R25 Share Capital Disclosure: Schedule of Stock Option HTML 29K
Activity (Tables)
29: R26 Share Capital Disclosure: Schedule of Stock HTML 27K
Options Outstanding (Tables)
35: R27 Share Capital Disclosure: Schedule of Warrant HTML 26K
Activity (Tables)
65: R28 Share Capital Disclosure: Schedule of Warrant HTML 31K
Details (Tables)
48: R29 Organization and Nature of Operations: Going HTML 25K
Concern (Details)
51: R30 Related Party Transactions Disclosure: Schedule of HTML 34K
Amounts Due to Related Parties (Details)
56: R31 Related Party Transactions Disclosure: Schedule of HTML 31K
Transactions with Related Parties (Details)
40: R32 Inventory Disclosure (Details) HTML 37K
23: R33 Other Current Assets Disclosure (Details) HTML 25K
50: R34 Equipment Disclosure: Amortization schedule for HTML 32K
the equipment (Details)
55: R35 Unearned Revenue Disclosure: Changes to Unearned HTML 34K
Revenue (Details)
39: R36 Unearned Revenue Disclosure (Details) HTML 36K
22: R37 Unearned Revenue Disclosure: Schedule of Loss on HTML 30K
Reacquisition of Distribution Rights (Details)
49: R38 Revenue Disclosure: Schedule of Revenue and HTML 41K
Associated Costs (Details)
57: R39 Notes and Advances Payable Disclosure: Schedule of HTML 42K
Short-term Loans and Advances Outstanding
(Details)
44: R40 Notes and Advances Payable Disclosure (Details) HTML 39K
62: R41 Share Capital Disclosure (Details) HTML 40K
32: R42 Share Capital Disclosure: Schedule of Stock Option HTML 30K
Activity (Details)
24: R43 Share Capital Disclosure: Schedule of Stock HTML 32K
Options Outstanding (Details)
43: R44 Share Capital Disclosure: Schedule of Warrant HTML 28K
Activity (Details)
61: R45 Share Capital Disclosure: Schedule of Warrant HTML 38K
Details (Details)
31: R46 Subsequent Event Disclosure (Details) HTML 31K
60: XML IDEA XML File -- Filing Summary XML 110K
54: EXCEL IDEA Workbook of Financial Reports XLSX 46K
13: EX-101.INS XBRL Instance -- cmxc-20200229 XML 571K
15: EX-101.CAL XBRL Calculations -- cmxc-20200229_cal XML 65K
16: EX-101.DEF XBRL Definitions -- cmxc-20200229_def XML 270K
17: EX-101.LAB XBRL Labels -- cmxc-20200229_lab XML 461K
18: EX-101.PRE XBRL Presentations -- cmxc-20200229_pre XML 419K
14: EX-101.SCH XBRL Schema -- cmxc-20200229 XSD 116K
47: ZIP XBRL Zipped Folder -- 0001393905-20-000119-xbrl Zip 56K
| ex-10.62 |
LOAN AGREEMENT
Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on January 9, 2020.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from January 9, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
| LENDER | BORROWER |
| Longview Investment Limited | Cell MedX Corp. |
|
|
|
| Per: |
Per: |
|
|
|
|
|
|
| /s/ Rick Donaldson | /s/ Yanika Silina |
| Name: Rick Donaldson | Yanika Silina, CFO |
PROMISSORY NOTE
| Principal Amount: USD$15,000 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $15,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from January 9, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/14/20 | None on these Dates | ||
| For Period end: | 2/29/20 | |||
| 1/9/20 | ||||
| List all Filings | ||||